Patents by Inventor Lisa Lock

Lisa Lock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10080739
    Abstract: Therapeutically effective 2,4,5-trisubstituted imidazole compounds are provided. Also provided are methods of preparing the compounds and pharmaceutical compositions comprising the compounds alone or in combination with other agents.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: September 25, 2018
    Assignee: Aptose Biosciences Inc.
    Inventors: Mario Huesca, Raed Al-Qawasmeh, Aiping H. Young, Yoon Lee, Lisa Lock
  • Publication number: 20150374669
    Abstract: Therapeutically effective 2,4,5-trisubstituted imidazole compounds are provided. Also provided are methods of preparing the compounds and pharmaceutical compositions comprising the compounds alone or in combination with other agents.
    Type: Application
    Filed: January 22, 2015
    Publication date: December 31, 2015
    Inventors: Mario HUESCA, Raed AL-QAWASMEH, Aiping H. YOUNG, Yoon LEE, Lisa LOCK
  • Patent number: 8148392
    Abstract: 2-indolyl imidazo[4,5-d]phenanthroline compounds of Formula (I) and methods of using same in the treatment of cancer, in particular, solid cancers and leukemia are provided. Pharmaceutical compositions comprising the compounds are also provided.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: April 3, 2012
    Assignee: Lorus Therapeutics Inc.
    Inventors: Mario Huesca, Aiping H. Young, Yoon Lee, Aye Aye Khine, Jim A. Wright, Lisa Lock, Raed Al-Qawasmeh
  • Publication number: 20100168417
    Abstract: 2-indolyl imidazo[4,5-d]phenanthroline compounds of Formula I that are capable of intracellular chelation of transition metals and of exerting antiproliferative effects in cancer cells, that are cytostatic and/or cytotoxic, are provided. Compounds of Formula I can also induce apoptosis in cancer cells and are thus capable of exerting a cytotoxic effect on cancer cells. The compounds of Formula I are also capable of selectively inhibiting the proliferation of one or more of prostate cancer cells, colon cancer cells, non-small lung cancer cells and leukemia cells. The compounds of Formula I are also capable of increasing the expression of the zinc-regulated tumour suppressor, KLF4 and thus are useful in inhibiting the proliferation of cancer cells in which KLF4 functions as a tumour-suppressor, including, but not limited to, bladder cancer, cancers of the gastrointestinal tract and various leukemias.
    Type: Application
    Filed: May 25, 2006
    Publication date: July 1, 2010
    Inventors: Mario Huesca, Aiping H. Young, Yoon Lee, Aye Aye Khine, Jim A. Wright, Lisa Lock, Raed Al-Qawasmeh